C vs CUE · P/E 16, rev $85.22B vs rev $9.3M
Citigroup Inc. (C) versus Cue Biopharma (CUE) — a side-by-side from cached financials, not a winner call.
Citigroup Inc. (C) is a banks - diversified company listed on US.
Cue Biopharma (CUE) is a biotechnology company listed on US.
Latest reported C revenue for 2025-12-31 was $85.22B. Net income was $14.31B. Revenue was up 5.0% from 2024-12-31 to 2025-12-31. C currently screens at market cap $214.73B and trailing P/E 15.5.
Latest reported CUE revenue for 2024-12-31 was $9.3M. Net income was -$40.7M. Revenue was up 69.2% from 2023-12-31 to 2024-12-31. CUE currently screens at market cap $59.5M.
C currently screens at market cap $214.73B and trailing P/E 15.5. CUE currently screens at market cap $59.5M.
Not investment advice. Open the C and CUE stock pages for the full models.
Not investment advice.